WallStSmart

Neuraxis, Inc. (NRXS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Neuraxis, Inc. generates 477% more annual revenue ($4.28M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -170.1%. RVMD earns a higher WallStSmart Score of 24/100 (F).

NRXS

Avoid

22

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: -16.32

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NRXSSignificantly Overvalued (-80.2%)

Margin of Safety

-80.2%

Fair Value

$2.58

Current Price

$6.84

$4.26 premium

UndervaluedFair: $2.58Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NRXS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
79.5%10/10

Revenue surging 79.5% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

NRXS4 concerns · Avg: 3.5/10
Price/BookValuation
13.7x4/10

Trading at 13.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$84.21M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NRXS

The strongest argument for NRXS centers on Revenue Growth, Debt/Equity. Revenue growth of 79.5% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NRXS

The primary concerns for NRXS are Price/Book, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NRXS profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

NRXS carries more volatility with a beta of 1.48 — expect wider price swings.

NRXS is growing revenue faster at 79.5% — sustainability is the question.

NRXS generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 22/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Neuraxis, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?